Add Yahoo as a preferred source to see more of our stories on Google. (COLORADO SPRINGS) — A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in ...

(COLORADO SPRINGS) — A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in Southern Colorado frustrated. A Dexcom is responsible for monitoring ...

This year started with healthy gains for DexCom (NASDAQ: DXCM) stock, but they didn't last long. The medical device stock is now down by about 53% from the high-water mark it set in April. DexCom ...

In March, the FDA approved DexCom Inc‘s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is ...

Dexcom reported second-quarter results on Friday, July 26. Management lowered its forward revenue outlook because of unexpected challenges with its new glucose monitoring device. Dexcom's main ...

Dexcom Inc. and Insulet Corp. both reported introductions of their products into new countries on the eve of the 2024 American Diabetes Association annual meeting in Orlando, Fla. The two firms also ...

We recently published a list of the 10 Best Medical Device Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other ...

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--UpScriptHealth, the leading direct-to-patient telehealth company providing new distribution channels for pharmaceutical and medical device brands, announced today ...

We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other best medical device ...

DexCom reported disappointing earnings, missing estimates by 4% and lowering full-year growth expectations by ~$200 million. Sales in the U.S. market slowed, while international markets saw anemic ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

Abbott and DexCom depend heavily on continuous glucose monitoring (CGM) device sales. Vertex is developing therapies that could cure type 1 diabetes. If Vertex is successful, the CGM market could be ...